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Abstract
Background
Anemia is a common complication among patients with chronic kidney disease (CKD), and
it is associated with unfavorable clinical outcomes in patients with CKD independent of the
estimated glomerular filtration rate (eGFR). We assessed the association of the urinary
albumin-to-creatinine ratio (ACR) and eGFR with anemia in CKD patients.
Methods
We conducted a cross-sectional study using baseline data from the KoreaN Cohort Study
for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD). Multiple regression
analysis was performed to identify the independent association of albuminuria with anemia.
Furthermore, odds ratios for anemia were calculated by cross-categorization of ACR and
eGFR.
Results
Among 1,456 patients, the mean age was 53.5 ± 12.4 years, and the mean eGFR and ACR
were 51.9 ± 30.5 mL/min per 1.73 m2 and 853.2 ± 1,330.3 mg/g, respectively. Anemia was
present in 644 patients (40.5%). Multivariate analysis showed that the odds ratio of anemia
increased according to ACR levels, after adjusting for age, sex, eGFR, body mass index, pulse
pressure, cause of CKD, use of erythropoiesis stimulating agents, serum calcium and ferritin
(ACR < 30mg/g as a reference group; 30–299mg/g, adjusted odds ratio (OR) = 1.43, 95%
confidence interval (CI) = 0.88–2.33;300mg/g, adjusted OR = 1.86, 95%CI = 1.12–3.10). In
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addition, graded associations were observed in cross-categorized groups of a higher ACR and
eGFR compared to the reference group with an ACR <30mg/g and eGFR60mL/min per
1.73 m2.
Conclusion
The present study demonstrated that albuminuria was a significant risk factor for anemia in
CKD patients independent of the eGFR.
Introduction
The incidence and prevalence of chronic kidney disease (CKD) have rapidly increased world-
wide, and CKD is recognized as a risk factor for all-cause mortality and cardiovascular mortal-
ity [1]. Anemia is a common complication in patients with CKD [2], and is associated with
poorer quality of life, heart failure, and the rapid decline of renal function [3–5]. In addition,
anemia is an independent risk factor for cardiovascular morbidity and mortality [4, 6]. Anemia
in CKD patients is largely due to a deficiency in renal production of erythropoietin (EPO),
although a deficiency of iron, folate or vitamin B12 can be another possible contributing factor.
However, it remains unclear whether the main cause of anemia is a loss of EPO production
capacity or a derangement in oxygen sensing [7]. Moreover, the increased prevalence of anemia
in diabetic patients with albuminuria, as a marker of kidney damage, has not been explained by
reduced renal function [8, 9]. When the relationship between albuminuria and anemia are elu-
cidated, this may lead to improving the treatment of anemia.
Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for
the Evaluation and Management of CKD recommended that CKD is classified based on the
cause of CKD and the estimated glomerular filtration rate (eGFR) category, and the albumin-
uria category (CGA) [10]. To date, a numerous data have demonstrated that albuminuria is an
independent predictor for all-cause mortality, cardiovascular disease, and CKD progression
[11–14]. However, little is known about the relationship between albuminuria and anemia in
CKD patients [1, 8, 15]. Therefore, in this study, we investigated whether albuminuria is signif-
icantly associated with anemia in patients with CKD.
Materials and Methods
Ethics statement
The study protocol was approved by the institutional review board at each participating clinical
center including the Seoul National University Hospital, Severance Hospital, Kangbuk Sam-
sung Medical Center, Seoul St. Mary’s Hospital, Gil Hospital, Eulji General Hospital, Chonnam
National University Hospital and Pusan Paik Hospital in 2011. All participating patients pro-
vided written informed consent.
Subjects
We used baseline data of the KoreaN Cohort Study for Outcome in Patients With Chronic Kid-
ney Disease (KNOW-CKD), a nationwide prospective cohort including CKD stage 1–5 non-
dialysis patients from February 2011 to July 2014. The study aimed to explore the risk factors
for renal or cardiovascular outcomes in Korean CKD populations. The detailed design and
methods of the KNOW-CKD have been previously published [16]. Among 1,528 patients
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initially included, 72 were excluded due to following reasons: a missing eGFR or urinary albu-
min-to-creatinine ratio (ACR) data in 58 patients and missing hemoglobin levels in 14. Finally,
1,456 patients were analyzed in the final analysis.
Data collection
Baseline demographics, and clinical and laboratory values were extracted from the electronic
data management system (PhactaX). Blood samples were analyzed at each hospital laboratory
of the participating centers. Ten mL of whole blood was obtained by using the serum separa-
tion tube (SST) and centrifuged within 1 hour for serum separation before being sent to the
central laboratory (Lab Genomics) for creatinine measurement. Serum creatinine was mea-
sured by an IDMS-traceable method and the eGFR was estimated using the CKD Epidemiology
Collaboration equation using age, sex, race, and the serum creatinine level [17]. Another 15 mL
of the first-voided urine was also collected to analyze urinary concentrations of albumin and
creatinine at the central laboratory, and the ACR was expressed as mg/g. Albuminuria was
determined by urinary ACR from spot urine samples. Subjects were categorized into three
groups according to the ACR (A1, A2, and A3), which were defined as ACR<30, 30–299, and
300 mg/g, respectively. In addition, we measured the protein excretion rate using timed urine
collection at each respective hospital. Anemia was defined using the World Health Organiza-
tion guideline: hemoglobin<12 g/dL for women and<13 g/dL for men [18]. The serum iron,
total iron-binding capacity (TIBC), and serum ferritin were measured, and the transferrin satu-
ration (TSAT, %) was calculated as (iron/TIBC) × 100. The body mass index (BMI) was calcu-
lated as weight in kg divided by the square of height in m. Two-dimensional echocardiography
was performed to measure cardiac parameters, and the left ventricular mass index (LVMI) was
calculated by dividing the LV mass by the body surface area at each respective hospital.
Statistical analyses
Continuous variables were expressed as mean ± standard deviation and categorical variables as
a number (percentage). The ACR was analyzed as a categorical variable and as a natural log-
transformed variable (Ln ACR) to approximate a normal distribution. To compare baseline
characteristics according to the ACR groups, analysis of variance and chi-square tests were
used for continuous variables and categorical variables, respectively. Spearman’s correlation
analysis was used to determine the association between hemoglobin and Ln ACR. We per-
formed univariate logistic regression analysis to determine the association between anemia and
other variables including demographics and various laboratory data. Multivariate logistic
regression analysis was applied to calculate adjusted odds ratio (OR) by stepwise backward
selection with adjustment for covariate effects to those variables that were significantly as-
sociated with anemia in univariate analysis. Missing variables were replaced using the linear
interpolation imputation method. Moreover, ORs were ascertained by model approaches
for covariate adjustment as follows: model 1 = adjusted for age and sex; model 2 = model
1 + eGFR; and mode 3 = model 2 + cause of CKD, BMI, use of an erythropoiesis stimulating
agent (ESA), pulse pressure, serum calcium, and ferritin. Graphical illustrations of the relation-
ship of the ACR and eGFR with anemia were also obtained by generalized additive models.
Additionally, we evaluated multiplicative interaction based on categories of the combination of
eGFR and ACR.We compared the risk in nine categories of the eGFR (<45, 45–59,60 mL/min
per 1.73 m2) and albuminuria (ACR<30, 30–299,300 mg/g). Generalized additive models
were computed using the R Statistical package software (version 2.15.3), and SPSS software, ver-
sion 19.0 (SPSS Inc.) was used to perform the remaining statistical analyses. Tests were consid-
ered statistically significant at P< 0.05.
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Results
Baseline characteristics of subjects
Among 1,456 patients, the mean age was 53.5 ± 12.4 years, and 896 patients (61.5%) were
male. The mean eGFR and ACR were 51.9 ± 30.5 mL/min per 1.73 m2 and 853.2 ± 1,330.3 mg/
g, respectively. Glomerulonephritis (35.9%) was the most common cause of CKD, followed by
diabetic nephropathy (21.6%), hypertensive nephropathy (20.2%), and polycystic kidney dis-
ease (17.4%). Two hundred twenty two patients (15.2%) had an eGFR90 mL/min per 1.73
m2, 268 (18.4%) had an eGFR of 60–89 mL/min per 1.73 m2, 227 (15.6%) had an eGFR of 45–
59 mL/min per 1.73 m2, 316 (21.7%) had an eGFR of 30–44 mL/min per 1.73 m2, 317 (21.8%)
had an eGFR of 15–29 mL/min per 1.73 m2, and 106 (7.3%) had an eGFR<15 mL/min per
1.73 m2. A2 (ACR 30–299 mg/g) and A3 (ACR300 mg/g) were present in 455 (31.3%) and
774 (53.2%) patients, respectively. The mean hemoglobin levels were 12.8 ± 1.9 g/dL, and 644
patients (44.2%) had anemia at baseline. One hundred-twenty seven patients (8.7%) were tak-
ing ESA therapy. Baseline clinical characteristics stratified by categories of ACR are presented
in Table 1. Subjects with macroalbuminuria were more likely to have diabetes mellitus and ane-
mia. The systolic blood pressure, LVMI, BMI, and parathyroid hormone were significantly
higher in the higher–ACR group. Meanwhile, the eGFR and levels of serum albumin, calcium,
and total cholesterol were significantly lower in the higher ACR group. No significant differ-
ence in age, sex, smoking history, and C-reactive protein, and serum ferritin levels was detected
among the three groups. Baseline demographics and the laboratory value according to the
cause of CKD are shown in S1 Table.
Associations between anemia and other variables
Pearson’s correlation analysis showed that hemoglobin levels were inversely related with Ln
ACR levels (r = -0.296, P< 0.001) (Fig 1). Univariate logistic regression was performed to ana-
lyze associations between anemia and other variables (S1 Table). We found that old age, female
sex, diabetes mellitus, a previous history of cardiovascular disease, and non-current smokers
were significantly associated with higher odds of anemia. CKD patients with the lowest quintile
of TSAT and the lowest or the highest quintile of ferritin were significantly associated with ane-
mia. A higher pulse pressure, LVMI, and serum uric acid and phosphorus levels were associ-
ated with anemia, whereas a lower BMI and lower levels of serum albumin, cholesterol, and
calcium were related to anemia.
Albuminuria as an independent risk factor for anemia
The prevalence rates and multivariable-adjusted ORs for anemia according to the ACR catego-
ries are presented in Table 2. Crude prevalence rates of anemia according to the ACR increased
across a higher ACR group. When adjusted for the eGFR, age and sex, populations with macro-
albuminuria had a two fold increase in the OR of anemia compared to those with normoalbu-
minuria. Furthermore, in the fully adjusted model, macroalbuminuria was still associated with
an increased risk of anemia. This analysis was considerably powered enough (adjusted R2 for
fully adjusted model was 0.387). Otherwise, microalbuminuria failed to show a significant
increase in the prevalence of anemia compared with the reference group. When patients using
an ESA were regarded as those with anemia or were excluded in multivariate analysis, the value
of OR for anemia was not noticeably changed (S3 and S4 Tables).
The adjusted ORs for anemia associated with ACR, as a continuous variable, were calculated
using generalized additive models. Fig 2 shows that lower levels of the eGFR and higher levels
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of the ACR were associated with anemia after adjusting for age, sex, the ACR (for the eGFR),
and the eGFR (for the ACR), as continuous variables.
Table 1. Baseline characteristics of subjects according to albuminuria.
Characteristics ACR (mg/g) P-value
<30 (N = 227) 30–299 (N = 455) 300 (N = 774)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 52.8 ± 13.4 53.5 ± 12.1 53.7 ± 12.2 0.59
BMI (kg/m2) 23.9 ± 3.2 24.1 ± 3.2 24.8 ± 3.4 <0.001
SBP (mmHg) 125.1 ± 14.2 125.7 ± 15.0 130.1 ± 17.3 <0.001
DBP (mmHg) 76.8 ± 10.9 76.0 ± 10.4 77.2 ± 11.5 0.18
MAP (mmHg) 92.9 ± 11.1 92.6 ± 10.9 94.9 ± 12.3 <0.01
Pulse pressure (mmHg) 48.3 ± 10.0 49.6 ± 11.4 52.9 ± 12.7 <0.001
eGFR (mL/min per 1.73 m2) 72.8 ± 30.1 53.2 ± 28.6 44.9 ± 28.7 <0.001
PCR (mg/g) 53.0 ± 43.4 216.6 ± 133.6 2,205.7 ± 2,398.3 <0.001
24-h urine protein (mg/day) 143.6 ± 640.4 314.7 ± 299.1 2,132.4 ± 2,178.0 <0.001
Hemoglobin (g/dL) 13.77 ± 1.56 12.96 ± 1.84 12.46 ± 2.07 <0.001
Ferritin (ng/mL) 143.3 ± 133.9 136.9 ± 143.1 138.0 ± 148.5 0.86
TSAT (%) 33.3 ± 13.1 30.9 ± 11.7 31.3 ± 12.3 0.05
Albumin (g/dL) 4.40 ± 0.26 4.31 ± 0.29 4.04 ± 0.44 <0.001
Total cholesterol (mg/dL) 174.6 ± 32.3 169.2 ± 33.2 175.7 ± 40.9 0.01
Calcium (mg/dL) 9.27 ± 0.37 9.21 ± 0.46 9.01 ± 0.58 <0.001
Phosphorus (mg/dL) 3.50 ± 0.52 3.57 ± 0.59 3.84 ± 0.71 <0.001
PTH (pg/mL) 50.9 ± 48.4 64.3 ± 54.8 87.4 ± 90.3 <0.001
Uric acid (mg/dL) 6.13 ± 1.90 6.99 ± 1.91 7.54 ± 1.91 <0.001
CRP (mg/L) 0.15 ± 0.37 0.22 ± 0.59 0.20 ± 0.51 0.26
LVMI (g/m2) 87.3 ± 22.1 91.9 ± 25.1 99.0 ± 30.3 <0.001
N (%) N (%) N (%)
Male sex 148 (65.2%) 268 (58.9%) 480 (62.0%) 0.26
Smokers 45 (19.8%) 68 (15.0%) 127 (16.4%) 0.28
Cause of CKD <0.001
DM 9 (4.0%) 67 (14.7%) 240 (31.0%)
HTN 72 (31.7%) 96 (21.1%) 129 (16.7%)
GN 24 (10.6%) 148 (32.5%) 345 (44.6%)
PKD 108 (47.6%) 125 (27.5%) 22 (2.8%)
Unclassiﬁed 14 (6.2%) 19 (4.2%) 38 (4.9%)
Hypertension 196 (89.1%) 414 (94.3%) 718 (95.7%) 0.001
Diabetes mellitus 30 (13.6%) 108 (24.6%) 329 (43.9%) <0.001
Cardiovascular disease 29 (13.2%) 72 (16.4%) 126 (16.8%) 0.43
Use of iron agent 16 (7.1%) 66 (14.6%) 132 (17.1%) 0.001
Use of ESA 7 (3.1%) 29 (6.4%) 91 (11.8%) <0.001
ACEI use 18 (9.0%) 43 (10.0%) 117 (15.4%) <0.01
ARB use 157 (78.9%) 360 (83.5%) 628 (82.8%) 0.34
Data are expressed as mean (with standard deviation) or number (%).
Abbreviations: ACR, albumin-to-creatinine ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass
index; CKD, chronic kidney disease; CRP, C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetic mellitus; eGFR,
estimated glomerular ﬁltration rate; ESA, erythropoiesis stimulating agent; GN, glomerulonephritis; HTN, hypertension; LVMI, left ventricular mass index;
MAP, mean arterial pressure; PCR, protein-to-creatinine ratio; PKD, polycystic kidney disease; PTH, parathyroid hormone; SBP, systolic blood pressure;
TSAT, transferrin saturation.
doi:10.1371/journal.pone.0139747.t001
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In multivariate regression analysis, variables that were significantly related to anemia are
presented in S5 Table.
Joint associations of albuminuria and the eGFR with anemia
We further examined the joint association between albuminuria and the eGFR with the risk of
anemia by calculating ORs based on the cross-categorization of ACR and eGFR (Table 3).
Compared to the reference groups of eGFR60 mL/min per 1.73 m2 and ACR<30 mg/g, the
ORs for anemia of groups with an ACR 30–299 mg/g or ACR300 mg/g in each eGFR cate-
gory showed an increasing trend according to the ACR.
Discussion
The results of this study showed that albuminuria was significantly associated with a higher
prevalence of anemia in patients with CKD, independent of the eGFR. Furthermore, graded
Fig 1. Correlation of hemoglobin levels with albuminuria.Hemoglobin levels are inversely related with Ln
ACR levels (r = -0.281, P < 0.001). Abbreviation: ACR, albumin-to-creatinine ratio; Ln ACR, log-transformed
albumin-to-creatinine ratio
doi:10.1371/journal.pone.0139747.g001
Table 2. Odds ratios for anemia associated with ACR.
Prevalence rates OR (95% CI)
ACR (mg/g) N (%) Model 1 Model 2 Model 3
<30 44 (19.4%) 1 (reference) 1 (reference) 1 (reference)
30–299 181 (39.8%) 2.69 (1.83–3.96) 1.48 (0.96–2.28) 1.43 (0.88–2.33)
300 419 (54.1%) 5.00 (3.47–7.21) 2.11 (1.40–3.17) 1.86 (1.12–3.10)
Anemia (hemoglobin <13 g/dL for men, <12 g/dL for women).
Model 1: adjusted for age and sex (adjusted R2 = 0.106, P = 0.028)
Model 2: adjusted for age, sex, and the eGFR (adjusted R2 = 0.296, P = 0.123)
Model 3: adjusted for age, sex, the eGFR, serum calcium level, BMI, pulse pressure, use of ESA, smoking, the cause of CKD, and ferritin level (adjusted
R2 = 0.387, P = 0.005)
Abbreviations: ACR, albumin creatinine ratio; eGFR, estimated GFR; CI, conﬁdence interval; BMI, body mass index; ESA, erythropoiesis stimulating
agent; CKD, chronic kidney disease.
doi:10.1371/journal.pone.0139747.t002
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associations were also found in the cross-categorized group of macroalbuminuria (ACR 300
mg/g) compared with normoalbuminuria (ACR< 30 mg/g) in every eGFR category.
Anemia is a common manifestation of CKD and the prevalence of anemia increases as the
eGFR declines [2]. Anemia is associated with a poorer quality of life and the rapid decline of
renal function, as well as cardiovascular mortality [3, 4, 19]. Anemia is mainly caused by insuf-
ficient kidney EPO production and a deficiency of the available iron to support ongoing eryth-
ropoiesis in CKD patients. However, several different factors including inflammation,
malnutrition, and metabolic disease, have been considered to contribute to the anemia of CKD.
Besides, previous studies have demonstrated that people with diabetes were more likely to have
anemia compared to those without diabetes [8, 9]. Furthermore, anemia was more frequently
present in a diabetic population with albuminuria compared to those without albuminuria [8,
9]. To date, several studies have demonstrated that albuminuria is a strong and independent
predictor for the progression of kidney disease, development of cardiovascular disease, and
Fig 2. The risk of anemia in relation to the ACR and eGFR. By using generalized additive models, the risk (solid line) and 95% confidence intervals
(dashed line) of anemia in relation to the (A) ACR and (B) eGFR is estimated. Abbreviations: ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular
filtration rate.
doi:10.1371/journal.pone.0139747.g002
Table 3. Odds ratios for anemia based on the cross-categorization of albuminuria and the eGFR.
eGFR (mL/min per 1.73 m2) ACR (mg/g) Non-anemia (N = 812) Anemia (N = 644) OR (95% CI)1
60 <30 126 (15.5) 12 (1.9) 1 (reference)
30–299 131 (16.1) 23 (3.6) 1.88 (0.86–4.09)
300 159 (19.6) 39 (6.1) 3.10 (1.42–6.77)
45–59 <30 29 (3.6) 10 (1.5) 4.51 (1.62–12.57)
30–299 56 (6.9) 26 (4.0) 5.30 (2.34–12.01)
300 63 (7.8) 43 (6.7) 7.39 (3.30–16.55)
<45 <30 28 (3.4) 22 (3.4) 7.75 (3.09–19.42)
30–299 87 (10.7) 132 (20.5) 13.30 (6.50–27.25)
300 133 (16.4) 337 (52.3) 18.73 (9.06–38.75)
1 Adjusted for age, sex, the cause of CKD, BMI, pulse pressure, ferritin and serum calcium levels, and the use of an ESA (adjusted R2 = 0.357, P = 0.187)
Abbreviations: ACR, albumin-to-creatinine ratio; BMI, body mass index; CI, conﬁdence interval; CKD, chronic kidney disease; eGFR, estimated glomerular
ﬁltration rate; ESA, erythropoiesis stimulating agent; OR, odds ratio.
doi:10.1371/journal.pone.0139747.t003
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mortality [11, 14, 20, 21]. The predictive ability of albuminuria at all categories of the eGFR
suggested that albuminuria categories should be added to the CKD staging system [10]. How-
ever, a limited number of data were available for the association between albuminuria and ane-
mia [1, 8, 15]. In the National Health and Nutrition Examination Survey (NHANES) data from
the United States, anemia was associated with the ACR at certain eGFR strata (40–59 and
120 mL/min per 1.73 m2) in a general population of 30,528 people[1]. However, although
this study had a large population size, there were few people with decreased renal function
(5.5%, eGFR<60 mL/min per 1.73 m2) and macroalbuminuria (3.1%, ACR300 mg/g). In
another cross-sectional study that included 820 patients with diabetes, the prevalence of ane-
mia were stratified according to the albumin excretion rate (<20, 20–200, and>200 μg/min)
and eGFR (<60, 60–80, and>80 mL/min per 1.73 m2). Subjects with macroalbuminuria were
more likely to have anemia at all the eGFR categories [8]. Furthermore, in the Chronic Renal
Insufficiency Cohort (CRIC) study, a multicenter observational study of 3,030 participants
with mild to severe CKD, a higher ACR and urinary protein creatinine ratio were associated
with lower serum hemoglobin levels. However, subjects with preserved eGFR were not
included in the CRIC study [15]. Unlike the NHANES data, the present study found that there
was a graded increase between anemia and albuminuria when the ACR and eGFR were cross-
categorized. However, the CRIC study showed an association between ACR and level of serum
hemoglobin after adjusting for the eGFR; in our study, anemia was defined by the World
Health Organization, and it was related to albuminuria when further adjusted for age, sex,
eGFR, and iron status.
The increased prevalence of anemia in diabetic patients with albuminuria cannot be
explained by reduced renal function [8, 9]. Some authors have proposed that significant losses
of transferrin in heavy proteinuria resulted in iron-deficiency anemia [22, 23]. Others have sug-
gested that endothelial dysfunction and microvascular damage in the renal tubulointerstitium
which were thought to be the pathogenesis of albuminuria, can lead to the impairment of EPO
production and release [24–27]. Tubulointerstitial injury is a major feature of diabetic
nephropathy and also reflects influences in other forms of renal disease[28]. Unal et al. found
that anemia was frequent among kidney transplant recipients with microalbuminuria and they
suggested that a tubulointerstitial injury of chronic allograft nephropathy leads to erythropoie-
tin deficiency, which starts even before significant deterioration of excretory renal function has
occurred [29]. In addition, a recent study demonstrated that a low hemoglobin level predicted
the progression or development of albuminuria in those with type 2 diabetes [30]. The authors
proposed that the leakage of protein which is thought to be an important contributor to pro-
gressive tubulointerstitial injury, may cause ineffective erythropoiesis in renal tubulointersti-
tium. Indeed, further experimental studies are needed to explore the delicate interaction
mechanisms between impaired endothelial function and erythropoiesis. Based on these find-
ings, we surmised that anemia, an upcoming early marker of microvascular damage and tubu-
lointerstitial injury, can precede declining renal function, similar to albuminuria. However, this
issue should be confirmed by further studies on the serial correlation between changes in renal
function and hemoglobin levels. In the present study, according to the recommendations of
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of CKD, we clas-
sified participants according to the cause of CKD, eGFR, and albuminuria categories, and
found that there was a graded association between albuminuria and anemia. In addition, diabe-
tes mellitus, as a cause of CKD, was independently associated with higher odds of anemia irre-
spective of the eGFR and albuminuria. Therefore, our finding can serve as additional evidence
to support the CGA staging system (the cause, GFR, and albuminuria) by KDIGO.
In our study, serum ferritin and TSAT levels, as measures of the iron deficiency status, were
feasible in most of the study subjects. The lowest TSAT quintile, and the lowest and highest
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serum ferritin quintiles showed a high OR for anemia. Measuring TSAT and the serum ferritin
are well-established tests for assessing iron status. However, since serum ferritin is an acute-
phase reactant, high ferritin concentrations should be interpreted with caution. In the present
study, there was a correlation between serum ferritin levels and the Ln C-reactive protein level
(r = 0.104, P< 0.001). A U-shaped relationship between the serum ferritin level and anemia
was also observed. Although serum ferritin levels were included in multivariable analysis, the
association between anemia and albuminuria remained significant. Compared to previous
studies, reliable data and adjusting the iron deficiency status could be the strengths of this
study. Meanwhile, considering the association between anemia and albuminuria, it can be
hypothesized that recognizing of patients with albuminuria and the use of interventions such
as angiotensin converting enzyme inhibitors (ACEI) or an angiotensin receptor blocker (ARB)
may lead to the improvement of anemia. However, ACEI has been suggested as causing anemia
in several studies rather than improving anemia [31, 32]. In a retrospective analysis from elec-
tronic health record data of 701 patients receiving ACEI or an ARB, the use of ACEI was asso-
ciated with decreased hemoglobin levels compared with an ARB [31]. In another retrospective
cohort study including 14,754 patients taking ACEI and 751 patients taking ARB, hemoglobin
levels were reduced during the first year of using ACEI and and ARB [32]. In the current study,
ACEI (versus non-user, OR = 1.06, 95% CI = 0.77–1.45, P = 0.73) and ARB (versus non-user,
OR = 1.10, 95% CI = 0.83–1.45, P = 0.52) were not significantly associated with anemia. Based
on these findings, we inferred that there were no definitive conclusions of the role of ACEI or
an ARB on anemia. The therapeutic use of ACEI or an ARB for anemia may need to be investi-
gated in a further prospective randomized controlled study.
There are several limitations of this study. First, only a single ACR measurement was avail-
able at baseline. ACR level may be high due to extremely low levels of creatinine as well as high
levels of albuminuria. However, the 24-hour urine collection was obtained from most of the
study population, and the protein excretion rate was measured, showing excellent correlation
with the ACR. Although timed urine collection (usually for 24 h) remains the gold standard
assessment of proteinuria, measurement of the ACR is more convenient, and it showed superi-
ority in predicting renal events [33]. Second, more than a third of the study population had
CKD caused by glomerulonephritis. This is because glomerulonephritis was defined by the
presence of glomerular hematuria or albuminuria with or without underlying systemic disease
causing glomerulonephritis. Third, this is a cross-sectional analysis, so we were not able to
determine causality in the relationship between albuminuria and anemia. Finally, since the
prevalence of anemia is very low in populations with an eGFR>90 mL/min per 1.73 m2,
patients with eGFR60 mL/min per 1.73 m2 were not further categorized into>90 and 60–89
mL/min per 1.73 m2 group according to CKD staging recommendations in multiplicative cate-
gorization between the eGFR and albuminuria [10, 21]. Likewise, since the number of subjects
with a decreased eGFR (<30 ml/min per 1.73m2) and normoalbuminuria was small, groups
with eGFR<45 mL/min per 1.73 m2 were not further categorized into CKD stages 3b, 4, and 5.
Notwithstanding these limitations, the simultaneous measurement of the ACR and creatinine
in a central laboratory and the enrollment of CKD patients with a preserved eGFR are the
major strengths of this study.
In conclusion, the present study demonstrated that albuminuria was significantly associated
with an increased prevalence of anemia, independently of eGFR, in patients with CKD.
Supporting Information
S1 Table. Univariate logistic regression analysis for the risk of anemia. Abbreviations: ACR,
albumin to creatinine ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
Albuminuria and Anemia in CKD
PLOSONE | DOI:10.1371/journal.pone.0139747 October 2, 2015 9 / 12
receptor blocker; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease;
DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-
stimulating agent; GN, glomerulonephritis; HTN, hypertension; LVMI, left ventricular mass
index; OR, Odds ratio; PCR, protein to creatinine ratio; PKD, polycystic kidney disease; PTH,
parathyroid hormone; SBP, systolic blood pressure; TSAT, transferrin saturation.
(DOCX)
S2 Table. Univariate logistic regression analysis for the risk of anemia. Abbreviations: ACR,
albumin to creatinine ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease;
DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-
stimulating agent; GN, glomerulonephritis; HTN, hypertension; LVMI, left ventricular mass
index; OR, Odds ratio; PCR, protein to creatinine ratio; PKD, polycystic kidney disease; PTH,
parathyroid hormone; SBP, systolic blood pressure; TSAT, transferrin saturation.
(DOCX)
S3 Table. Odds ratio for anemia associated with ACR. Anemia (hemoglobin<13 g/dL for
men,<12 g/dL for women or with use of ESA). Model 1: adjusted for age and sex. Model 2:
adjusted for age, sex, and the eGFR. Model 3: adjusted for age, sex, the eGFR, serum calcium
level, BMI, use of an ESA, smoking, the cause of CKD, and ferritin level. Abbreviations: ACR,
albumin creatinine ratio; eGFR, estimated GFR; CI, confidence interval; BMI, body mass
index; ESA, erythropoiesis stimulating agent; CKD, chronic kidney disease.
(DOCX)
S4 Table. Odds ratio for anemia associated with ACR (patients with ESA are excluded).
Anemia (hemoglobin<13 g/dL for men,<12 g/dL for women). Model 1: adjusted for age and
sex.Model 2: adjusted for age, sex, and the eGFR.Model 3: adjusted for age, sex, the eGFR,
serum calcium level, BMI, use of an ESA, smoking, the cause of CKD, and ferritin level. Abbre-
viations: ACR, albumin creatinine ratio; eGFR, estimated GFR; CI, confidence interval; BMI,
body mass index; ESA, erythropoiesis stimulating agent; CKD, chronic kidney disease.
(DOCX)
S5 Table. Multivariate logistic regression analysis for the risk of anemia. Abbreviations:
ACR, albumin to creatinine ratio; BMI, body mass index; CI, confidence interval; CKD, chronic
kidney disease; DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; ESA,
erythropoiesis-stimulating agent; GN, glomerulonephritis; HTN, hypertension; OR, Odds
ratio; PCR, protein to creatinine ratio; PKD, polycystic kidney disease.
(DOCX)
Acknowledgments
Conceived and designed the experiments: JSH KHC. Performed the experiments: JSHMJL
KSP KHC. Analyzed the data: JSHMJL SKP JYL. Contributed reagents/materials/analysis
tools: SHH THY KHO YYHWKC YHK CRA. Wrote the paper: JSH MJL KHC.
Author Contributions
Conceived and designed the experiments: JSH KHC. Performed the experiments: JSHMJL
KSP KHC. Analyzed the data: JSHMJL SKP JYL. Contributed reagents/materials/analysis
tools: SHH THY KHO YYHWKC YHK CRA. Wrote the paper: JSH MJL KHC.
Albuminuria and Anemia in CKD
PLOSONE | DOI:10.1371/journal.pone.0139747 October 2, 2015 10 / 12
References
1. Inker LA, Coresh J, Levey AS, Tonelli M, Muntner P. Estimated GFR, Albuminuria, and Complications
of Chronic Kidney Disease. Journal of the American Society of Nephrology. 2011; 22(12):2322–31. doi:
10.1681/asn.2010111181 PMID: 21965377
2. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the
Third National Health and Nutrition Examination Survey (1988–1994). Archives of internal medicine.
2002; 162(12):1401–8. Epub 2002/06/22. PMID: 12076240.
3. Babazono T, Hanai K, Suzuki K, Kiuchi Y, Inoue A, Tanaka M, et al. Lower haemoglobin level and sub-
sequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia.
2006; 49(6):1387–93. Epub 2006/04/14. doi: 10.1007/s00125-006-0247-y PMID: 16612589.
4. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men
with moderate and severe chronic kidney disease. Kidney international. 2006; 69(3):560–4. Epub
2006/01/06. doi: 10.1038/sj.ki.5000105 PMID: 16395253.
5. Al-Ahmad A, RandWM, Manjunath G, KonstamMA, Salem DN, Levey AS, et al. Reduced kidney func-
tion and anemia as risk factors for mortality in patients with left ventricular dysfunction. Journal of the
American College of Cardiology. 2001; 38(4):955–62. Epub 2001/10/05. PMID: 11583864.
6. Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, et al. Effects of anemia
and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. Jour-
nal of the American Society of Nephrology: JASN. 2005; 16(6):1803–10. Epub 2005/04/29. doi: 10.
1681/asn.2004070597 PMID: 15857925.
7. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V, et al. Inhibition of prolyl
hydroxylases increases erythropoietin production in ESRD. Journal of the American Society of
Nephrology: JASN. 2010; 21(12):2151–6. Epub 2010/12/01. doi: 10.1681/asn.2010010116 PMID:
21115615; PubMed Central PMCID: PMCPmc3014028.
8. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized Anemia in Patients
With Diabetes A cross-sectional survey. Diabetes care. 2003; 26(4):1164–9. PMID: 12663591
9. Adetunji OR, Mani H, Olujohungbe A, Abraham KA, Gill GV. 'Microalbuminuric anaemia'—the relation-
ship between haemoglobin levels and albuminuria in diabetes. Diabetes research and clinical practice.
2009; 85(2):179–82. Epub 2009/06/02. doi: 10.1016/j.diabres.2009.04.028 PMID: 19481284.
10. KDIGO. 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease.
http://kdigo.org/home/guidelines/ckd-evaluation-management. Available from: http://kdigo.org/home/.
11. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al. The relationship between magni-
tude of proteinuria reduction and risk of end-stage renal disease: results of the African American study
of kidney disease and hypertension. Archives of internal medicine. 2005; 165(8):947–53. Epub 2005/
04/27. doi: 10.1001/archinte.165.8.947 PMID: 15851648.
12. Bello AK, Hemmelgarn B, Lloyd A, JamesMT, Manns BJ, Klarenbach S, et al. Associations among esti-
mated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clinical journal of
the American Society of Nephrology: CJASN. 2011; 6(6):1418–26. Epub 2011/04/30. doi: 10.2215/cjn.
09741110 PMID: 21527648; PubMed Central PMCID: PMCPmc3109940.
13. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower esti-
mated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative
meta-analysis of general and high-risk population cohorts. Kidney international. 2011; 80(1):93–104.
Epub 2011/02/04. doi: 10.1038/ki.2010.531 PMID: 21289597.
14. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin
excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation.
2002; 106(14):1777–82. Epub 2002/10/03. PMID: 12356629.
15. Fisher H, Hsu CY, Vittinghoff E, Lin F, Bansal N. Comparison of associations of urine protein-creatinine
ratio versus albumin-creatinine ratio with complications of CKD: a cross-sectional analysis. American
journal of kidney diseases: the official journal of the National Kidney Foundation. 2013; 62(6):1102–8.
Epub 2013/09/18. doi: 10.1053/j.ajkd.2013.07.013 PMID: 24041612; PubMed Central PMCID:
PMCPmc3840083.
16. Oh KH, Park SK, Park HC, Chin HJ, Chae DW, Choi KH, et al. KNOW-CKD (KoreaN cohort study for
Outcome in patients With Chronic Kidney Disease): design and methods. BMC nephrology. 2014;
15:80. Epub 2014/06/03. doi: 10.1186/1471-2369-15-80 PMID: 24884708; PubMed Central PMCID:
PMCPmc4050398.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to esti-
mate glomerular filtration rate. Annals of internal medicine. 2009; 150(9):604–12. Epub 2009/05/06.
PMID: 19414839; PubMed Central PMCID: PMCPmc2763564.
Albuminuria and Anemia in CKD
PLOSONE | DOI:10.1371/journal.pone.0139747 October 2, 2015 11 / 12
18. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vita-
min and Mineral Nutrition Information System, 1993–2005. Public health nutrition. 2009; 12(4):444–54.
Epub 2008/05/24. doi: 10.1017/s1368980008002401 PMID: 18498676.
19. Horwich TB, Fonarow GC, Hamilton MA, MacLellanWR, Borenstein J. Anemia is associated with
worse symptoms, greater impairment in functional capacity and a significant increase in mortality in
patients with advanced heart failure. Journal of the American College of Cardiology. 2002; 39
(11):1780–6. Epub 2002/06/01. PMID: 12039491.
20. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardio-
vascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA: the journal of
the American Medical Association. 2001; 286(4):421–6. Epub 2001/07/31. PMID: 11466120.
21. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classifica-
tion, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney inter-
national. 2011; 80(1):17–28. Epub 2010/12/15. doi: 10.1038/ki.2010.483 PMID: 21150873.
22. Howard RL, Buddington B, Alfrey AC. Urinary albumin, transferrin and iron excretion in diabetic
patients. Kidney international. 1991; 40(5):923–6. Epub 1991/11/01. PMID: 1762297.
23. Prinsen BH, de Sain-van der Velden MG, Kaysen GA, Straver HW, van Rijn HJ, Stellaard F, et al.
Transferrin synthesis is increased in nephrotic patients insufficiently to replace urinary losses. Journal
of the American Society of Nephrology: JASN. 2001; 12(5):1017–25. Epub 2001/04/24. PMID:
11316861.
24. Thomas MC, Cooper ME, Rossing K, Parving HH. Anaemia in diabetes: Is there a rationale to TREAT?
Diabetologia. 2006; 49(6):1151–7. Epub 2006/04/06. doi: 10.1007/s00125-006-0215-6 PMID:
16586069.
25. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G. Anemia with impaired erythropoie-
tin response in diabetic patients. Archives of internal medicine. 2005; 165(4):466–9. Epub 2005/03/02.
doi: 10.1001/archinte.165.4.466 PMID: 15738380.
26. Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease? Nature Clinical Prac-
tice Nephrology. 2007; 3(1):20–30. PMID: 17183259
27. Thomas M, Tsalamandris C, MacIsaac R, Jerums G. Anaemia in diabetes: an emerging complication of
microvascular disease. Current diabetes reviews. 2005; 1(1):107–26. Epub 2008/01/29. PMID:
18220587.
28. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an
aftermath of glomerular injury? Kidney international. 1999; 56(5):1627–37. Epub 1999/11/26. doi: 10.
1046/j.1523-1755.1999.00721.x PMID: 10571771.
29. Unal A, Kocyigit I, Arikan T, Sipahioglu MH, Tokgoz B, Oymak O. Microalbuminuria is associated with
high prevalence of anemia in renal transplant recipients. Transplantation proceedings. 2013; 45
(3):949–52. Epub 2013/04/30. doi: 10.1016/j.transproceed.2013.02.066 PMID: 23622595.
30. Okada H, Hasegawa G, Tanaka M, Osaka T, Shiotsu Y, Narumiya H, et al. Association between Hemo-
globin Concentration and the Progression or Development of Albuminuria in Diabetic Kidney Disease.
PloS one. 2015; 10(5):e0129192. Epub 2015/05/30. doi: 10.1371/journal.pone.0129192 PMID:
26023923; PubMed Central PMCID: PMCPmc4449165.
31. Ajmal A, Gessert CE, Johnson BP, Renier CM, Palcher JA. Effect of angiotensin converting enzyme
inhibitors and angiotensin receptor blockers on hemoglobin levels. BMC research notes. 2013; 6:443.
Epub 2013/11/06. doi: 10.1186/1756-0500-6-443 PMID: 24188157.
32. Leshem-Rubinow E, Steinvil A, Zeltser D, Berliner S, Rogowski O, Raz R, et al. Association of angio-
tensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients
without renal failure. Mayo Clinic proceedings. 2012; 87(12):1189–95. Epub 2012/11/13. doi: 10.1016/j.
mayocp.2012.07.020 PMID: 23141116; PubMed Central PMCID: PMCPmc3547548.
33. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, et al. Com-
parison of different measures of urinary protein excretion for prediction of renal events. Journal of the
American Society of Nephrology: JASN. 2010; 21(8):1355–60. Epub 2010/07/17. doi: 10.1681/asn.
2010010063 PMID: 20634296; PubMed Central PMCID: PMCPmc2938598.
Albuminuria and Anemia in CKD
PLOSONE | DOI:10.1371/journal.pone.0139747 October 2, 2015 12 / 12
